Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of results from a Phase II regulatory study for its KRAS G12C inhibitor, glecirasib, at the 2024 American Society of Clinical Oncology (ASCO) Plenary Series.
In terms of efficacy, the study reported a confirmed objective response rate (ORR) of 47.9% (56/117) in patients with second-line non-small cell lung cancer (NSCLC), with 4 patients achieving a complete response (CR) and 36 patients experiencing a tumor reduction of over 50%. The disease control rate (DCR) was 86.3%. The median progression-free survival (mPFS) was 8.2 months, and the median overall survival (mOS) was 13.6 months. Data on the median duration of relief (mDoR) is not yet mature, but the response duration ratio was 73.6% and 56.6% at 6 and 12 months, respectively. Safety-wise, glecirasib demonstrated favorable safety characteristics, with no grade five side effects reported and only a 5% discontinuation rate, showing good gastrointestinal safety compared to other KRAS G12C inhibitors.
Developed in-house by Jacobio, glecirasib is currently under investigation in multiple studies across China, the United States, and Europe for the treatment of NSCLC, colorectal cancer, and pancreatic cancer. The drug has received orphan drug designation (ODD) in the US and breakthrough therapy designation (BTD) in China for certain indications.- Flcube.com
